United BioSource Acquires Interest in Leading Adaptive Design Technology Servic...( UBC ClinResearch to Expand Gl...)

UBC ClinResearch to Expand Global Reach in Pioneering Field

BETHESDA, Md., Sept. 10 /PRNewswire/ -- United BioSource Corporation (UBC) today announced the acquisition of an ownership interest in ClinResearch GmbH, a global leader in technology solutions and services for flexible, or adaptive, clinical trials. Headquartered in Cologne, Germany, with more than 100 employees, ClinResearch has designed and implemented 80 adaptive programs over the past seven years. ClinResearch's co-founder, Reinhard Eisebitt, is a co-developer of the leading software used by pharmaceutical companies and contract research organizations (CROs) throughout the world to support the rigorous statistical requirements of adaptive trials.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070910/NEM007LOGO )

ClinResearch, which will now operate under the name UBC ClinResearch, will be a centerpiece of UBC's adaptive design clinical trial offering and will deliver a full service, global solution for pharmaceutical, biotechnology and medical device companies seeking to capitalize on the benefits of adaptive design in their clinical development strategy.

"We are thrilled to welcome ClinResearch to the UBC family," said Ethan Leder, CEO of UBC. "Having worked with the founders for several years, we know that they are an excellent fit with our culture and vision. They are innovative and science driven, and have built a world-class organization with a track record of developing and executing technology solutions that we plan to introduce aggressively to our growing base of sponsor and CRO clients."

"The interest in adaptive design is accelerating from the early adopter to the rapid growth stage. We are excited to be joining an organization with the resources to allow us to capitalize on this opportunity," noted Michael Fischer, PhD, founder of ClinResearch. Fischer added, "We are mo
'/>"/>